Retina is a Marker for Cerebrovascular Heath

Conditions

• Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
• Cerebral Microbleeding
• Cerebral Small Vessel Diseases
• Sporadic White Matter Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Cilostazol — DRUG
  Cilostazol 100mg BID

Study Details

Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.

Key Dates

Start date

Feb 9, 2021

Status verified

Jul 2025

Primary completion

Jun 30, 2026

Completion

Jun 30, 2026

Study Design

Enrollment

100 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: Cilostazol
  Cilostazol 100mg BID
• No Intervention: No intervention

Primary Outcome Measure

white matter disease volume [ Time Frame: 1 year ]

Central Contacts

• Meredith McDonald
  904-953-4200
  [email protected]

Locations (1)

Find similar trials in Jacksonville, FL